Aardvark Therapeutics, Inc.
Income Statement
| Line Item | FY2025 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $48.9M |
| SG&A Expense | $13.8M |
| Operating Income | $-62.7M |
| Operating Margin | — |
| Interest Expense | — |
| Pretax Income | — |
| Income Tax Expense | $0 |
| Net Income | $-57.6M |
| Net Margin | — |
| EPS (Basic) | $-2.93 |
| EPS (Diluted) | $-2.93 |
| Shares Outstanding (Basic) | 19.6M |
| Shares Outstanding (Diluted) | 19.6M |
| Dividends Per Share | — |